Latest triazolam Stories
Stonehaven demonstrates their dedication to maintaining customer satisfaction.
TITUSVILLE, N.J., Dec. 13, 2010 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S.
REDWOOD CITY, Calif., Oct. 22 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.
REDWOOD CITY, Calif., Oct. 14 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that Nigel Ray has joined the company as Vice President of Business Development. In this new position, Mr.
Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan.
Research and Markets (http://www.researchandmarkets.com/research/370328/inhaled_cns_therap) has announced the addition of the "Inhaled CNS Therapeutics - Markets & Opportunities" report to their offering. Delivering drugs to the central nervous system presents unique challenges.
By Bill Berkrot NEW YORK (Reuters) - An experimental insomnia drug being developed by Merck & Co. and Danish drug maker H. Lundbeck A/S showed promise in helping patients achieve deep sleep in small mid-stage clinical studies, the companies said on Wednesday.
No single sleeping pill stands out as the best, according to a U.S. review of the newer sleep aids on the market.